Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/ki.1983.87 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Roxadustat-Induced Central Hypothyroidism Masked by Uremia at the Initiation of Hemodialysis: A Case Report.
Cureus
December 2024
Nephrology, Yokohama Municipal Citizen's Hospital, Yokohama, JPN.
Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is a novel class of orally administered medications for renal anemia in patients with end-stage renal disease (ESRD). Roxadustat, a HIF-PHI, has a structure similar to that of triiodothyronine and may work as an agonist for thyroid hormone receptor-beta in the pituitary gland and/or hypothalamus. Therefore, roxadustat may cause central hypothyroidism due to suppressing thyroid-stimulating hormone (TSH) release in the pituitary gland and/or thyrotropin-releasing hormone release in the hypothalamus.
View Article and Find Full Text PDFEfficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial.
Nephrol Dial Transplant
November 2024
Department of Medicine and Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Background And Hypothesis: Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for treatment of anemia in dialysis patients with CKD in some parts of the world. This subgroup analysis examined the efficacy and safety of daprodustat versus darbepoetin alfa in patients with anemia of CKD undergoing peritoneal dialysis (PD).
Methods: ASCEND-D (NCT02879305) was an open-label, Phase 3 trial; patients with CKD were randomized to daprodustat daily and epoetin alfa (HD patients) or darbepoetin alfa (PD patients).
Efficacy of Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitors in Renal Anemia: Enhancing Erythropoiesis and Long-Term Outcomes in Patients with Chronic Kidney Disease.
Biomedicines
December 2024
Division of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Nishi-cho 36-1, Yonago 683-8504, Tottori, Japan.
Background/objectives: Renal anemia is one of the major complications associated with chronic kidney disease (CKD). Erythropoietin-stimulating agents (ESAs) are commonly used; however, some patients exhibit resistance. Hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHIs) have emerged as a novel treatment for renal anemia, enhancing erythropoiesis and iron metabolism.
View Article and Find Full Text PDFThe role and clinical implications of HIF-PHI daprodustat in dialysis-dependent and non-dialysis-dependent chronic kidney disease anemic patients: a general review.
Front Nephrol
December 2024
Department of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Chronic kidney disease (CKD) patients often suffer from complications such as anemia as the kidney function declines. More than 25% of CKD hemodialysis patients in China are complicated with renal anemia due to renal and hepatic impairment in the production of erythropoietin (EPO). In recent years, prolyl hydroxylase domain (PHD) inhibitors have been approved in China and Japan for the treatment of CKD patients complicated with anemia.
View Article and Find Full Text PDFVascular and Perivascular Role in the Regulation of Angiogenesis: Impact on Arteriovenous Fistula Maturation.
Arch Intern Med Res
November 2024
Department of Translational Research, College of the Osteopathic Medicine of the Pacific Western University of Health Sciences, Pomona, California 91766 USA.
Arteriovenous fistula (AVF) is a surgical connection between an artery and a vein created in patients with end-stage renal disease needing dialysis. A major concern with AVF is maturation failure which results, while creating a new AVF, a troublesome process for the patients. Thus, maturation of AVF is important which is achieved by outflow tract outward remodeling.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!